Impact of Combination Drugs on the Transcriptome Profiles of Triple-Negative Breast Cancer Cells

Authors:
Preprint
Publisher website
Google Scholar
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer and poses significant treatment challenges due to fewer available options. Creating highly specific and precise anticancer therapies continues to be a significant challenge for TNBC. Previous studies showed that combining drugs or adding chemotherapy to other therapies has significantly improved patient prognosis and proved to be an effective strategy for treating TNBC compared to using chemotherapeutic drugs alone targeting TNBC pathways. One such combination is a PARP inhibitor (PARPi) with an immune checkpoint inhibitor (ICI). In this study, we explored the transcriptomic profiles of the combination of Olaparib (a PARP inhibitor) and atezolizumab (a monoclonal antibody targeting PD-L1) in cells derived from African American (AA) and White populations. Our results demonstrated that combining Olaparib (Ola) and Atezolizumab (Atz) significantly reduced cell viability in both AA and White cell lines, compared to either agent alone. Our transcriptional profiling results showed that in both up- and down-regulated genes, there was widespread suppression of proliferation and biosynthetic gene networks, and selective activation of immune and stress-related pathways. Our transcriptional profiling revealed that both up- and down-regulated genes exhibited widespread suppression of proliferation and biosynthesis pathways, along with selective activation of immune and stress-related pathways. Our functional enrichment analysis revealed significant changes in DNA damage response, chromatin organization, RNA regulatory processes, immune signaling, and inflammatory responses. In conclusion, our study’s results provide valuable insights into key features of combination therapy, which may help guide the more targeted development of these regimens.

This publication has 34 references indexed in Scilit: